Gout & crystal arthritis

Comparative Cardiovascular Safety of Nonsteroidal Anti‐Inflammatory Drug Versus Colchicine Use When Initiating Urate‐Lowering Therapy Among Patients With Gout: Target Trial Emulations

Arthritis RheumatolPublished Target trial emulation

Authors' conclusion

In these target trial emulations of patients with gout starting allopurinol, NSAID prophylaxis was associated with a higher risk of MACE than colchicine or no prophylaxis

Study context

Population
Adults with gout starting allopurinol (83.5% male, mean age 60.9 years)propensity score-matched
Participants
18,120 adults
Comparison
Nonsteroidal anti-inflammatory drugs (NSAIDs) vs colchicine for gout flare prophylaxis when starting allopurinol
Outcome
Major adverse cardiovascular events (MACE):
  • MI
  • Stroke
  • Cardiovascular death
Methodological detailsnew-user comparative effectiveness study, sequential, propensity score-matched, inverse probability of treatment weighting (IPTW) sensitivity analysis
  • New-user comparative effectiveness study
  • Sequential
  • Propensity score-matched
  • IPTW sensitivity analysis

Main finding

As reported in the abstract

MACE
Each group vs colchicineRate difference, per 1,000 person-years (95% CI)
NSAIDs
38.8(15.4–62.2)
Each group vs colchicineHazard ratio (95% CI)
NSAIDs
1.56(1.11–2.17)

Further findings

OutcomeRate difference (per 1,000 person-years) (95% CI)
Cardiovascular deathNSAIDsvs Colchicine10.9 (0.7–21.1)
OutcomeHR (95% CI)
Cardiovascular deathNSAIDsvs Colchicine2.50 (1.14–5.26)
MACE,vs no prophylaxis1.50 (1.17–1.91)
MI,vs no prophylaxis1.93 (1.35–2.75)

Original publication

Comparative Cardiovascular Safety of Nonsteroidal Anti‐Inflammatory Drug Versus Colchicine Use When Initiating Urate‐Lowering Therapy Among Patients With Gout: Target Trial Emulations. Arthritis Rheumatol. Published 29 July 2025. doi:10.1002/art.43259

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.